Document is current

Article History

Received: 13 August 2025

Accepted: 18 December 2025

First Online: 5 January 2026

Declarations

:

: Ethical approval (Reference No. 25-12338-BO) was approved by the ethics committee of the medical faculty of the University Duisburg-Essen and the survey was conducted in compliance with the Declaration of Helsinki. Informed consent to participate was obtained from all participants (for details of the informed consent see Supplement 1).

: Not applicable.

: WS received travel support for participation in congresses and / or (speaker) honoraria as well as research grants from medi GmbH Bayreuth, Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi Genzyme, Takeda, and UCB outside of the present publication. SB received speaker honoraria from Astra-Zeneca, Grünenthal AG, Grünenthal GmbH, Lilly, Janssen outside of the present publication, JE received travel support for participation in congresses and / or (speaker) honoraria from Bayer AG, Grünenthal, Hexal AG; Active positions in scientific societies: German Society for Anesthesiology and Intensive Care Medicine e.V.; Member of the executive committee, Section spokesperson for Pain Medicine, First spokesperson for the Scientific Working Group on Pain Medicine; German Pain Society (Member of the advisory board. All other authors declare no conflicts of interest.